Repurposed Medications in Oncology: What Does the Research Say About Metformin and Statins?

Developing a brand-new cancer drug from scratch is one of the slowest and most expensive processes in the world.

On average, it takes between ten and fifteen years and costs more than one billion dollars to bring a single novel oncology molecule from the laboratory bench through clinical trials and regulatory approval. Even then, newly approved therapies often cost thousands of dollars per month, placing immense financial strain on families.

Because of this bottleneck, medical researchers around the globe have turned their attention toward an innovative strategy called drug repurposing (also called off-label drug repositioning).

During our research into Jane McLelland’s Metro Map and the Metabolic Theory of Cancer, Dr. Jean and I were surprised to discover that several inexpensive, widely used generic medications have demonstrated compelling anti-cancer mechanisms in preclinical and clinical studies.

Here is what the published science actually says about repurposed drugs, with a focus on two of the most thoroughly studied compounds: Metformin and Statins.

, –

What Is Drug Repurposing in Oncology?

The Direct Answer (AEO Summary):
Drug repurposing in oncology is the practice of investigating medications that are already approved by regulatory bodies (such as the FDA) for common non-cancer conditions (like diabetes, cardiovascular disease, or bacterial infections) to determine if they possess secondary mechanisms that inhibit cancer cell metabolism, disrupt tumor pathways, or sensitize malignant cells to standard chemotherapy and radiation.

Because these medications have been prescribed to millions of patients for decades, their safety profiles, liver metabolism, common side effects, and maximum safe dosages are already thoroughly documented.

Researchers do not need to spend ten years discovering whether the drug is safe for humans. Instead, clinical trials can focus immediately on testing whether the drug provides clinical synergy when added to standard chemotherapy or immunotherapy regimens.

Specialized clinical research groups, such as the UK-based Care Oncology Clinic and global non-profits like the Repurposing Drugs in Oncology (ReDO) Project, actively catalog clinical trials evaluating these generic compounds.

, –

The Top Two Repurposed Medications Under Investigation

1. Metformin (Commonly Prescribed for Type 2 Diabetes)

Metformin is derived from the French lilac plant (Galega officinalis) and has been used safely for over sixty years to lower blood sugar in patients with diabetes.

In the mid-2000s, epidemiologists analyzing massive patient health registries noticed something remarkable: diabetic patients who were taking metformin had significantly lower incidence rates of cancer, and better survival outcomes if they did develop cancer, compared to diabetic patients taking insulin or other medications.

How It Works Against Cancer Cells:

• Inhibiting Mitochondrial Complex I: Inside cells, metformin mildly suppresses Complex I in the electron transport chain within mitochondria. This slows down ATP energy production and increases the AMP/ATP ratio.
• Activating AMPK & Shutting Down mTOR: In response to lower cellular energy, cells activate the AMPK (AMP-activated protein kinase) energy sensor. AMPK acts as a cellular brake pedal, shutting down mTOR (mammalian target of rapamycin), the primary biological accelerator pedal that signals tumors to grow and divide.
• Lowering Circulating Insulin and IGF-1: Metformin improves insulin sensitivity in the liver and muscles. This reduces overall circulating blood glucose and insulin levels. Because insulin and Insulin-like Growth Factor 1 (IGF-1) are potent growth stimulants for many cancers, lowering these systemic levels helps starve fermenting tumors.

Clinical trials have shown promising results when metformin is combined with standard therapies in breast, prostate, colorectal, and endometrial cancers.

, –

2. Statins (Commonly Prescribed for High Cholesterol)

Statins (such as Atorvastatin, Simvastatin, and Pravastatin) are widely prescribed to lower low-density lipoprotein (LDL) cholesterol by blocking an enzyme in the liver called HMG-CoA reductase.

In oncology research, statins block what Jane McLelland refers to as the Mevalonate pathway on the Metro Map.

How It Works Against Cancer Cells:

• Disrupting Cell Membrane Anchors: The Mevalonate pathway does not just produce cholesterol; it also produces lipid anchors called geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP). Cancer cells use these lipid anchors to attach critical oncogenic signaling proteins (like Ras and Rho) to the cell membrane. By depriving cells of these anchors, statins can cause cancer cells to detach and undergo programmed cell death (apoptosis).
• Targeting Cancer Stem Cells: Laboratory studies suggest that lipophilic statins (which easily penetrate cellular membranes, like simvastatin and atorvastatin) can impair the survival of therapy-resistant cancer stem cells.
• Sensitizing Tumors to Chemotherapy: In preclinical trials, adding a statin to standard chemotherapy protocols increased tumor cell sensitivity to chemotherapy drugs while inhibiting metastatic migration.

, –

Other Notable Repurposed Drugs in Clinical Studies

Beyond metformin and statins, researchers are actively evaluating several other generic medications:

• Mebendazole & Fenbendazole: Common anti-parasitic medications that bind to tubulin structures in cancer cells, inhibiting microtubule formation and glucose uptake in preclinical models.
• Doxycycline: A common tetracycline antibiotic that targets mitochondrial protein synthesis in cancer stem cells, impairing their ability to regenerate after chemotherapy.
• Low-Dose Naltrexone (LDN): Used at micro-dosages (1.5 mg to 4.5 mg) at bedtime to temporarily block opioid receptors, stimulating an endorphin rebound that modulates immune T-cell function and downregulates inflammatory signaling.

, –

Critical Safety Considerations: Why Medical Supervision Is Essential

While research into repurposed medications is exciting, patients must never attempt to self-prescribe or purchase unverified medications online.

Here is why strict medical oversight is non-negotiable:

1. Dangerous Drug-Drug Interactions: A repurposed medication can interact with your primary oncology drugs. For example, statins and certain targeted chemotherapy drugs share the same liver clearance pathways (the Cytochrome P450 enzyme system), which can cause drug levels to spike dangerously.
2. Organ Clearance & Kidney Stress: Chemotherapy places heavy demands on the kidneys and liver. Adding extra pharmaceuticals without regular blood testing for liver enzymes and kidney filtration can cause toxicity.
3. Tumor Specificity: Different cancers run on different fuels. Metformin may be beneficial for a glucose-avid tumor with high insulin receptors, but inappropriate for a patient experiencing severe cancer cachexia (muscle wasting) or hypoglycemia.

Always discuss repurposed protocols transparently with an integrative oncologist or your primary medical team.

, –

How Repurposed Medicine Fits “The 3-Pillar Pathway”

Within The 3-Pillar Pathway to Remission & Peace, repurposed medications sit right at the intersection of Pillar 1 (Modern Oncology) and Pillar 3 (Metabolic Terrain):

• They utilize legitimate pharmaceutical science and clinical trial data.
• They alter the systemic biological terrain (blood sugar, lipids, mitochondrial respiration) to make it harder for malignant cells to thrive.
• They are combined with natural botanicals (Pillar 2) and whole-body lifestyle habits to provide multi-layered defense.

, –

Where to Explore Next

• Previous Article (Day 3): The 10 Terrain Elements: How Dr. Nasha Winters Evaluates the Internal Environment
• Next Article (Day 5): Therapeutic Ketosis vs. Standard Keto: What Cancer Patients Need to Know
• Explore Our Protocol: My Actual Protocol: How I Went from Stage 4 to Remission
• Understand Our Philosophy: How We Help Other Cancer Patients Through Our 3-Pillar Model